“Pharmacy businesses need a clear pathway to a better future which they can both have confidence in and plan for,” says Community Pharmacy England Chief Executive Janet Morrison in a new blog. Community pharmacy owners are “exasperated and desperate” and the sector needs answers on a range of key issues. In her latest blog, Janet [...]
The post Update from our CEO appeared first on Community Pharmacy England.
The Government has today responded to the Health Select Committee’s report into the state of community pharmacy, addressing each of the report’s recommendations to support the sector. In its response, the Government has reaffirmed its ambition to expand the role of pharmacies and to improve workforce planning, but it has not set out answers to [...]
The post Government supports measures to extend pharmacy services, but hesitant on funding overhaul appeared first on Community Pharmacy England.
NHS England have announced, via their Primary Care Bulletin, that it will soon start to undertake provider assurance work with pharmacy owners providing the Flu Vaccination service. The reviews will engage with pharmacy owners who may have administered NHS flu vaccinations to adults outside of the announced and authorised cohorts prior to 3rd October 2024. [...]
The post Flu Vaccination service: Provider Assurance activity begins appeared first on Community Pharmacy England.
Department of Health and Social Care (DHSC) has issued a medicine supply notification for Apomorphine hydrochloride (APO-go® PFS) 50mg/10ml solution for infusion pre-filled syringes. MSN/2025/002 Tier 2 – medium impact Date of issue: 9th January 2025 APO-go® (apomorphine hydrochloride) PFS are being discontinued; supplies are anticipated to be exhausted from early April 2025. APO-go® POD [...]
The post Medicine Supply Notification: Apomorphine hydrochloride (APO-go® PFS) 50mg/10ml solution for infusion pre-filled syringes appeared first on Community Pharmacy England.
MHRA Class 4 Medicines Defect Notification: Rabeprazole sodium 10mg and 20mg gastro-resistant tablets (Bristol Laboratories Limited) Drug alert number: EL (25)A/01 Date issued: 09 January 2025 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Rabeprazole sodium 10mg and 20mg gastro-resistant tablets (Bristol Laboratories Limited) DMRC [...]
The post MHRA Class 4 Medicines Defect Notification: Rabeprazole sodium 10mg and 20mg gastro-resistant tablets (Bristol Laboratories Limited) appeared first on Community Pharmacy England.
Recent Comments